Internal Reference Number: FOI_8026
Date Request Received: 02/07/2024 00:00:00
Date Request Replied To: 15/07/2024 00:00:00
This response was sent via: By Email
Request Summary: Haematology and Immunoglobulin Treatments
Request Category: Companies
Question Number 1: In the past 3 months, how many patients have received the following treatments (for any disease): • Berinert (Human C1-esterase inhibitor) • Cinryze (Human C1-esterase inhibitor) • Firazyr (Icatibant) • Icatibant - any brand except Firazyr • Orladeyo (Berotralstat) • Ruconest (Recombinant human C1-esterase inhibitor) • Takhzyro (Lanadelumab) | |
Answer To Question 1: Please see attached response to Q1 To accompany this answer to question 1 please also see the documents listed below: FOI 8026 Question 1 complete.pdf | |
Question Number 2: In the past 3 months, how many patients have received the following immunoglobulin treatments (for any disease): • Cutaquig • Cuvitru • Gammagard • Gammanorm • Hizentra • Hyqvia • Intratect • Iqymune • Kiovig • Privigen • Octagam • Panzyga • Subgam • Any other normal immunoglobulin | |
Answer To Question 2: Please see attached document for response to Q2 To accompany this answer to question 2 please also see the documents listed below: FOI 8026 Question 2 complete.pdf | |
Please see Attachments: | |
To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.